Screener / SEC EDGAR /CIK 0001773751 /10-K filed Feb 23, 2026, compared with Feb 24, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Offices & Clinics of Doctors of Medicine

Hims & Hers Health, Inc. HIMS

Compare with peers Embed
What it said it expected, against what it reported

11 targets with a reported result

Releases of the last 3 years
Above the range 7 above the last range given
Within the range 4 of 11 range targets
Below the range 0 below the last range given

The numbers HIMS said it expected, in its earnings releases, next to what it then reported for the same period.

Target by target

Each target, with the sentence it came from · release and 10-Q or 10-K

The last range givenReported, abovewithin or keptbelow or missed
TargetWhat the company saidReportedResult
EBITDA (company-defined)
Fiscal 2026
Given $300.00M to $375.00M release Feb 23, 2026
Lowered $275.00M to $350.00M release May 11, 2026
Lowered $275.00M to $325.00M release Aug 10, 2026
Lowered $257.00M to $277.00M release Nov 9, 2026
– No standard number
The company's words
Provides Q1 and full year 2026 guidance 1 , with full year 2026 revenue in the range of $2.7 billion to $2.9 billion and Adjusted EBITDA in the range of $300 million to $375 million SAN FRANCISCO, February 23, 2026 – Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for th e fourth quarter and full year ended December 31, 2025 in a shareholder letter that is posted at investors.hims.com. release Feb 23, 2026
For the full year 2026, we expect: … Adjusted EBITDA of $275 million to $350 million, reflecting an Adjusted EBITDA margin of 10% to 12%. release May 11, 2026
For the full year 2026, we expect: … Adjusted EBITDA of $275 million to $325 million, reflecting an Adjusted EBITDA margin of 9% to 10%. release Aug 10, 2026
For the full year 2026, we expect: … Adjusted EBITDA of $257 million to $277 million, reflecting an Adjusted EBITDA margin of 8% to 9%. release Nov 9, 2026
Revenue
Fiscal 2026
Given $2.70B to $2.90B release Feb 23, 2026
Raised $2.80B to $3.00B release May 11, 2026
Raised $3.10B to $3.30B release Aug 10, 2026
Lowered $3.13B to $3.15B release Nov 9, 2026
– Not reported yet
The company's words
Provides Q1 and full year 2026 guidance 1 , with full year 2026 revenue in the range of $2.7 billion to $2.9 billion and Adjusted EBITDA in the range of $300 million to $375 million SAN FRANCISCO, February 23, 2026 – Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for th e fourth quarter and full year ended December 31, 2025 in a shareholder letter that is posted at investors.hims.com. release Feb 23, 2026
Raises full year 2026 revenue guidance 1 to a range of $2.8 billion to $3.0 billion and updates Adjusted EBITDA guidance to a range of $275 million to $350 million SAN FRANCISCO, May 11, 2026 – Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the first quarter ended March 31, 2026. release May 11, 2026
Raises full year 2026 revenue guidance to a range of $3.1 billion to $3.3 billion and updates Adjusted EBITDA guidance to a range of $275 million to $325 million SAN FRANCISCO, August 10, 2026 – Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading global health and wellness platform, today announced financial results for the second quarter ended June 30, 2026. release Aug 10, 2026
Tightens full year 2026 revenue guidance to a range of $3.13 billion to $3.15 billion and reduces Adjusted EBITDA guidance to a range of $257 million to $277 million SAN FRANCISCO, November 9, 2026 – Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading global health and wellness platform, today announced financial results for the third quarter ended September 30, 2026. release Nov 9, 2026
EBITDA (company-defined)
Q4 of fiscal 2026
Given $70.00M to $90.00M release Nov 9, 2026
– No standard number
The company's words
For the fourth quarter 2026, we expect: … Adjusted EBITDA of $70 million to $90 million, reflecting an Adjusted EBITDA margin of 8% to 10%. release Nov 9, 2026
Revenue
Q4 of fiscal 2026
Given $875.00M to $895.00M release Nov 9, 2026
– Not reported yet
The company's words
For the fourth quarter 2026, we expect: … Revenue of $875 million to $895 million. release Nov 9, 2026
EBITDA (company-defined)
Q3 of fiscal 2026
Given $75.00M to $95.00M release Aug 10, 2026
– No standard number
The company's words
For the third quarter 2026, we expect: … Adjusted EBITDA of $75 million to $95 million, reflecting an Adjusted EBITDA margin of 9% to 11%. release Aug 10, 2026
Revenue
Q3 of fiscal 2026
Given $880.00M to $900.00M release Aug 10, 2026
$890.37M
10-Q filed 2026-11-09
Within the range
The company's words
For the third quarter 2026, we expect: … Revenue of $880 million to $900 million. release Aug 10, 2026
Revenue
Q2 of fiscal 2026
Given $680.00M to $700.00M release May 11, 2026
$753.21M
10-Q filed 2026-08-10
Above the range
The company's words
For the second quarter 2026, we expect: … Revenue of $680 million to $700 million. release May 11, 2026
EBITDA (company-defined)
Fiscal 2025 (ended Dec 31, 2025)
Given $270.00M to $320.00M release Feb 24, 2025
Raised $295.00M to $335.00M release May 5, 2025
Kept $295.00M to $335.00M release Aug 4, 2025
Lowered $307.00M to $317.00M release Nov 3, 2025
– No standard number
The company's words
Provides Q1 and full year 2025 guidance, with full year 2025 revenue in the range of $2.3 billion to $2.4 billion and Adjusted EBITDA in the range of $270 million to $320 million SAN FRANCISCO, February 24, 2025 – Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for th e fourth quarter and full year ended December 31, 2024 in a shareholder letter that is posted at investors.hims.com. release Feb 24, 2025
For the full year 2025, we expect: … Adjusted EBITDA of $295 million to $335 million, reflecting an Adjusted EBITDA margin of 13% to 14%. release May 5, 2025
Affirms full year 2025 revenue guidance of $2.3 billion to $2.4 billion and Adjusted EBITDA guidance of $295 million to $335 million SAN FRANCISCO, August 4, 2025 – Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the second quarter ended June 30, 2025, in a shareholder letter that is posted at investors.hims.com. release Aug 4, 2025
Narrows full year 2025 revenue guidance to $2.335 billion to $2.355 billion and Adjusted EBITDA guidance to $307 million to $317 million SAN FRANCISCO, November 3, 2025 – Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the third quarter ended September 30, 2025, in a shareholder letter that is posted at investors.hims.com. release Nov 3, 2025
Revenue
Fiscal 2025 (ended Dec 31, 2025)
Given $2.30B to $2.40B release Feb 24, 2025
Kept $2.30B to $2.40B release May 5, 2025
Kept $2.30B to $2.40B release Aug 4, 2025
Lowered $2.33B to $2.35B release Nov 3, 2025
$2.35B
10-K filed 2026-02-23
Within the range
The company's words
Provides Q1 and full year 2025 guidance, with full year 2025 revenue in the range of $2.3 billion to $2.4 billion and Adjusted EBITDA in the range of $270 million to $320 million SAN FRANCISCO, February 24, 2025 – Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for th e fourth quarter and full year ended December 31, 2024 in a shareholder letter that is posted at investors.hims.com. release Feb 24, 2025
Affirms full year 2025 revenue guidance of $2.3 billion to $2.4 billion and raises Adjusted EBITDA guidance to a range of $295 million to $335 million release May 5, 2025
Affirms full year 2025 revenue guidance of $2.3 billion to $2.4 billion and Adjusted EBITDA guidance of $295 million to $335 million SAN FRANCISCO, August 4, 2025 – Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the second quarter ended June 30, 2025, in a shareholder letter that is posted at investors.hims.com. release Aug 4, 2025
Narrows full year 2025 revenue guidance to $2.335 billion to $2.355 billion and Adjusted EBITDA guidance to $307 million to $317 million SAN FRANCISCO, November 3, 2025 – Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the third quarter ended September 30, 2025, in a shareholder letter that is posted at investors.hims.com. release Nov 3, 2025
EBITDA (company-defined)
Q4 of fiscal 2025
Given $55.00M to $65.00M release Nov 3, 2025
– No standard number
The company's words
For the fourth quarter 2025, we expect: … Adjusted EBITDA of $55 million to $65 million, reflecting an Adjusted EBITDA margin of 9% to 10%. release Nov 3, 2025
Revenue
Q4 of fiscal 2025
Given $605.00M to $625.00M release Nov 3, 2025
$617.82M
10-K filed 2026-02-23
Within the range
The company's words
For the fourth quarter 2025, we expect: … Revenue of $605 million to $625 million. release Nov 3, 2025
EBITDA (company-defined)
Q3 of fiscal 2025
Given $60.00M to $70.00M release Aug 4, 2025
– No standard number
The company's words
For the third quarter 2025, we expect: … Adjusted EBITDA of $60 million to $70 million, reflecting an Adjusted EBITDA margin of 11% to 12%. release Aug 4, 2025
Revenue
Q3 of fiscal 2025
Given $570.00M to $590.00M release Aug 4, 2025
$598.98M
10-Q filed 2025-11-03
Above the range
The company's words
For the third quarter 2025, we expect: … Revenue of $570 million to $590 million. release Aug 4, 2025
EBITDA (company-defined)
Q2 of fiscal 2025
Given $65.00M to $75.00M release May 5, 2025
– No standard number
The company's words
For the second quarter 2025, we expect: … Adjusted EBITDA of $65 million to $75 million, reflecting an Adjusted EBITDA margin of 12% to 14%. release May 5, 2025
Revenue
Q2 of fiscal 2025
Given $530.00M to $550.00M release May 5, 2025
$544.83M
10-Q filed 2025-08-04
Within the range
The company's words
For the second quarter 2025, we expect: … Revenue of $530 million to $550 million. release May 5, 2025
EBITDA (company-defined)
Fiscal 2024 (ended Dec 31, 2024)
Given $100.00M to $120.00M release Feb 26, 2024
Raised $120.00M to $135.00M release May 6, 2024
Raised $140.00M to $155.00M release Aug 5, 2024
Raised $173.00M to $178.00M release Nov 4, 2024
– No standard number
The company's words
Provides Q1 and full year 2024 guidance, with full year 2024 revenue in the range of $1.17 billion to $1.20 billion and Adjusted EBITDA in the range of $100 million to $120 million SAN FRANCISCO, February 26, 2024 – Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the fourth quarter and full year ended December 31, 2023 in a shareholder letter that is posted at investors.hims.com. release Feb 26, 2024
Raises full year 2024 guidance to a range of $1.20 billion to $1.23 billion and Adjusted EBITDA to a range of $120 million to $135 million SAN FRANCISCO, May 6, 2024 – Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the first quarter ended March 31, 2024 in a shareholder letter that is posted at investors.hims.com. release May 6, 2024
Raises full year 2024 revenue guidance to a range of $1.37 billion to $1.40 billion and Adjusted EBITDA guidance to a range of $140 million to $155 million SAN FRANCISCO, August 5, 2024 – Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the second quarter ended June 30, 2024 in a shareholder letter that is posted at investors.hims.com. release Aug 5, 2024
Raises full year 2024 revenue guidance to a range of $1.460 billion to $1.465 billion and Adjusted EBITDA guidance to a range of $173 million to $178 million SAN FRANCISCO, November 4, 2024 – Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the third quarter ended September 30, 2024 in a shareholder letter that is posted at investors.hims.com. release Nov 4, 2024
Revenue
Fiscal 2024 (ended Dec 31, 2024)
Given $1.17B to $1.20B release Feb 26, 2024
Raised $1.20B to $1.23B release May 6, 2024
Raised $1.37B to $1.40B release Aug 5, 2024
Raised $1.46B to $1.47B release Nov 4, 2024
$1.48B
10-K filed 2025-02-24
Above the range
The company's words
Provides Q1 and full year 2024 guidance, with full year 2024 revenue in the range of $1.17 billion to $1.20 billion and Adjusted EBITDA in the range of $100 million to $120 million SAN FRANCISCO, February 26, 2024 – Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the fourth quarter and full year ended December 31, 2023 in a shareholder letter that is posted at investors.hims.com. release Feb 26, 2024
For the full year 2024, we expect: … Revenue of $1.20 billion to $1.23 billion. release May 6, 2024
Raises full year 2024 revenue guidance to a range of $1.37 billion to $1.40 billion and Adjusted EBITDA guidance to a range of $140 million to $155 million SAN FRANCISCO, August 5, 2024 – Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the second quarter ended June 30, 2024 in a shareholder letter that is posted at investors.hims.com. release Aug 5, 2024
Raises full year 2024 revenue guidance to a range of $1.460 billion to $1.465 billion and Adjusted EBITDA guidance to a range of $173 million to $178 million SAN FRANCISCO, November 4, 2024 – Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the third quarter ended September 30, 2024 in a shareholder letter that is posted at investors.hims.com. release Nov 4, 2024
EBITDA (company-defined)
Q4 of fiscal 2024
Given $50.00M to $55.00M release Nov 4, 2024
– No standard number
The company's words
For the fourth quarter 2024, we expect: … Adjusted EBITDA of $50 million to $55 million, reflecting an Adjusted EBITDA margin of 11% to 12%. release Nov 4, 2024
Revenue
Q4 of fiscal 2024
Given $465.00M to $470.00M release Nov 4, 2024
$481.14M
10-K filed 2025-02-24
Above the range
The company's words
For the fourth quarter 2024, we expect: … Revenue of $465 million to $470 million. release Nov 4, 2024
EBITDA (company-defined)
Q3 of fiscal 2024
Given $35.00M to $40.00M release Aug 5, 2024
– No standard number
The company's words
For the third quarter 2024, we expect: … Adjusted EBITDA of $35 million to $40 million, reflecting an Adjusted EBITDA margin of 9% to 11%. release Aug 5, 2024
Revenue
Q3 of fiscal 2024
Given $375.00M to $380.00M release Aug 5, 2024
$401.56M
10-Q filed 2024-11-04
Above the range
The company's words
For the third quarter 2024, we expect: … Revenue of $375 million to $380 million. release Aug 5, 2024
EBITDA (company-defined)
Q2 of fiscal 2024
Given $30.00M to $35.00M release May 6, 2024
– No standard number
The company's words
For the second quarter 2024, we expect: … Adjusted EBITDA of $30 million to $35 million, reflecting an Adjusted EBITDA margin of 10% to 12%. release May 6, 2024
Revenue
Q2 of fiscal 2024
Given $292.00M to $297.00M release May 6, 2024
$315.65M
10-Q filed 2024-08-05
Above the range
The company's words
For the second quarter 2024, we expect: … Revenue of $292 million to $297 million. release May 6, 2024
EBITDA (company-defined)
Q1 of fiscal 2024
Given $22.00M to $27.00M release Feb 26, 2024
– No standard number
The company's words
For the first quarter 2024, we expect: … Adjusted EBITDA of $22 million to $27 million, reflecting an Adjusted EBITDA margin of 8% to 10%. release Feb 26, 2024
Revenue
Q1 of fiscal 2024
Given $267.00M to $272.00M release Feb 26, 2024
$278.17M
10-Q filed 2024-05-06
Above the range
The company's words
For the first quarter 2024, we expect: … Revenue of $267 million to $272 million. release Feb 26, 2024

Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (12 releases since 2024-02-26), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.

Sources

The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.

Also

Earnings releases: each release in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/HIMS/export.csv") into a cell.

Next:Archive
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.